Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 11Completed 7Active not recruiting 6Withdrawn 4Terminated 4Not yet recruiting 1No longer available 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Thoracic 1Gastrointestinal 1

Conditions

Breast Neoplasms 4Stomach Neoplasms 1Meningeal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Trastuzumab 78Capecitabine 59Cyclophosphamide 54Paclitaxel 52Docetaxel 50Letrozole 44Fulvestrant 43Lapatinib 34Doxorubicin 31Carboplatin 31Vinorelbine 30Bevacizumab 29Anastrozole 28pembrolizumab 26exemestane 24Tamoxifen 23Gemcitabine 22Radiotherapy 21Albumin-Bound Paclitaxel 19Taxes 17Everolimus 17Epirubicin 15pertuzumab 13Ado-Trastuzumab Emtansine 13130-nm albumin-bound paclitaxel 13palbociclib 12Magnetic Resonance Spectroscopy 12liposomal doxorubicin 11atezolizumab 11Filgrastim 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms × tucatinib × Clear all
NCT05583110 2025-12-10

TrasTUCAN

Spanish Breast Cancer Research Group

Phase 2 Terminated
13 enrolled
Breast

Breast Neoplasms

NCT03501979 2025-08-29

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

University of Alabama at Birmingham

Phase 2 Terminated
17 enrolled 16 charts
Breast

Breast Neoplasms, Meningeal Neoplasms

NCT04789096 2025-06-06

TUGETHER

Breast Cancer Trials, Australia and New Zealand

Phase 2 Terminated
31 enrolled
Breast

Breast Neoplasms

NCT05091528 2022-08-18

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Silverback Therapeutics

Phase 1/2 Terminated
2 enrolled 9 charts
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡